We investigated the roles of FFA in mild cognitive impairment (MCI) of type 2 diabetes mellitus (T2DM) patients and determine its association with rs11868035 polymorphism.
Methods:
We recruited 191 Chinese T2DM patients into two groups through Montreal Cognitive Assessment. Demographic and clinical data were collected, multiple domain cognitive functions were tested, plasma FFA levels were measured through ELISA, and SREBP-1c rs11868035 genotype was detected using the Seqnome method.
Results:
In comparison with the healthy-cognition group (n = 128), the MCI group (n = 63) displayed lower glucose control (p = 0.012) and higher plasma FFA level (p = 0.021), which were independent risk factors of MCI in T2DM patients in multivariate regression analysis (OR = 1.270, p = 0.003; OR = 1.005, p = 0.036). Additionally, the plasma FFA levels of MCI patients were positively correlated with Stroop color word test-C time scores (r = 0.303, p = 0.021) and negatively related to apolipoprotein A1 levels (r = –0.311, p = 0.017), which are associated positively with verbal fluency test scores (r = 0.281, p = 0.033). Both scores reflected attention ability and executive function. Moreover, the G allele carriers of rs11868035 showed higher digit span test scores than non-carriers in T2DM patients (p = 0.019) but without correlation with plasma FFA levels.
Conclusion:
In T2DM, elevated plasma level of FFA, when combined with lower apolipoprotein A1 level portends abnormal cholesterol transport, were susceptible to early cognitive impairment, especially for attention and execution deficits. The G allele of SREBP-1c rs11868035 may be a protective factor for memory.
NCD Risk Factor Collaboration (NCD-RisC) (2016) Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet387, 1513–1530.
2.
ChoNH, ShawJE, KarurangaS, HuangY, da Rocha FernandesJD, OhlroggeAW, MalandaB (2018) IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract138, 271–281.
3.
LiW, WangT, XiaoS (2016) Type 2 diabetes mellitus might be a risk factor for mild cognitive impairment progressing to Alzheimer’s disease. Neuropsychiatr Dis Treat12, 2489–2495.
4.
GudalaK, BansalD, SchifanoF, BhansaliA (2013) Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig4, 640–650.
5.
PetersenRC (2000) Mild cognitive impairment: Transition between aging and Alzheimer’s disease. Neurologia15, 93–101.
6.
PetersenRC, DoodyR, KurzA, MohsRC, MorrisJC, RabinsPV, RitchieK, RossorM, ThalL, WinbladB (2001) Current concepts in mild cognitive impairment. Arch Neurol58, 1985–1992.
7.
SallamHS, TumurbaatarB, ZhangWR, TuvdendorjD, ChandaliaM, TempiaF, LaezzaF, TaglialatelaG, AbateN (2015) Peripheral adipose tissue insulin resistance alters lipid composition and function of hippocampal synapses. J Neurochem133, 125–133.
8.
YuanXY, WangXG (2017) Mild cognitive impairment in type 2 diabetes mellitus and related risk factors: A review. Rev Neurosci28, 715–723.
9.
KaiserS, SelznerL, WeberJ, SchallnerN (2020) Carbon monoxide controls microglial erythrophagocytosis by regulating CD36 surface expression to reduce the severity of hemorrhagic injury. Glia68, 2427–2445.
10.
Abd ElaatyTA, IsmailAA, SheshtawyHA, SultanEA, EbrahimMG (2019) Assessment of comorbid mild cognitive impairment and depression in patients with type 2 diabetes mellitus. Diabetes Metab Syndr13, 1759–1764.
11.
HeQ, LiQ, ZhaoJ, WuT, JiL, HuangG, MaF (2016) Relationship between plasma lipids and mild cognitive impairment in the elderly Chinese: A case-control study. Lipids Health Dis15, 146.
12.
Gonzalez-EscamillaG, AtienzaM, Garcia-SolisD, CanteroJL (2016) Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment. Brain Struct Funct221, 631–645.
13.
ZouY, ZhuQ, DengY, DuanJ, PanL, TuQ, DaiR, ZhangX, ChuLW, LüY (2014) Vascular risk factors and mild cognitive impairment in the elderly population in Southwest China. Am J Alzheimers Dis Other Demen29, 242–247.
14.
LewisTL, CaoD, LuH, MansRA, SuYR, JungbauerL, LintonMF, FazioS, LaDuMJ, LiL (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem285, 36958–36968.
15.
CaiR, HanJ, SunJ, HuangR, TianS, ShenY, DongX, XiaW, WangS (2016) Plasma clusterin and the CLU gene rs11136000 variant are associated with mild cognitive impairment in type 2 diabetic patients. Front Aging Neurosci8, 179.
16.
CaiR, HanJ, SunJ, HuangR, TianS, ShenY, WangS (2017) Effects of ABCA1 R219K polymorphism and serum lipid profiles on mild cognitive impairment in type 2 diabetes mellitus. Front Aging Neurosci9, 257.
17.
MerchedA, XiaY, VisvikisS, SerotJM, SiestG (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging21, 27–30.
18.
WuP, ZhaoY, ZhuangX, SunA, ZhangY, NiY (2018) Low glucagon-like peptide-1 (GLP-1) concentration in serum is indicative of mild cognitive impairment in type 2 diabetes patients. Clin Neurol Neurosurg174, 203–206.
WilsonDM, BinderLI (1997) Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer’s disease. Am J Pathol150, 2181–2195.
21.
PatilS, ChanC (2005) Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett384, 288–293.
22.
MarwarhaG, Claycombe-LarsonK, LundJ, SchommerJ, GhribiO (2019) A diet enriched in palmitate and deficient in linoleate exacerbates oxidative stress and amyloid-beta burden in the hippocampus of 3xTg-AD mouse model of Alzheimer’s disease. J Alzheimers Dis68, 219–237.
23.
TalbotK, YoungRA, Jolly-TornettaC, LeeVM, TrojanowskiJQ, WolfBA (2000) A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex. Neurochem Int37, 17–31.
24.
BloomGS (2014) Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol71, 505–508.
25.
FontehAN, CipollaM, ChiangJ, ArakakiX, HarringtonMG (2014) Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer’s disease. PLoS One9, e100519.
26.
DhopeshwarkarGA, MeadJF (1973) Uptake and transport of fatty acids into the brain and the role of the blood-brain barrier system. Adv Lipid Res11, 109–142.
27.
ChenCT, GreenJT, OrrSK, BazinetRP (2008) Regulation of brain polyunsaturated fatty acid uptake and turnover. Prostaglandins Leukot Essent Fatty Acids79, 85–91.
28.
YangWC, CaoHL, WangYZ, LiTT, HuHY, WanQ, LiWZ (2021) Inhibition of nitric oxide synthase aggravates brain injury in diabetic rats with traumatic brain injury. Neural Regen Res16, 1574–1581.
29.
ShimanoH (2002) Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm65, 167–194.
30.
YahagiN, ShimanoH, HastyAH, Amemiya-KudoM, OkazakiH, TamuraY, IizukaY, ShionoiriF, OhashiK, OsugaJ, HaradaK, GotodaT, NagaiR, IshibashiS, YamadaN (1999) A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem274, 35840–35844.
31.
HuaX, WuJ, GoldsteinJL, BrownMS, HobbsHH (1995) Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics25, 667–673.
32.
LiuJX, LiuJ, LiPQ, XieXD, GuoQ, TianLM, MaXQ, ZhangJP, GaoJY (2008) Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes mellitus, insulin resistance and blood lipid levels in Chinese population. Diabetes Res Clin Pract82, 42–47.
33.
Vargas-AlarconG, Gonzalez-PachecoH, Perez-MendezO, Posadas-SanchezR, Cardoso-SaldanaG, Ramirez-BelloJ, EscobedoG, Nieto-LimaB, FragosoJM (2019) SREBF1c and SREBF2 gene polymorphisms are associated with acute coronary syndrome and blood lipid levels in Mexican population. PLoS One14, e0222017.
34.
GrarupN, Stender-PetersenKL, AnderssonEA, JorgensenT, Borch-JohnsenK, SandbaekA, LauritzenT, SchmitzO, HansenT, PedersenO (2008) Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: A study of 15,734 Danish subjects. Diabetes57, 1136–1142.
35.
HuangX, WangC, TianS, HuangR, GuoD, ZhangH, ShiJ, WangS (2019) Higher plasma level of Nampt presaging memory dysfunction in Chinese type 2 diabetes patients with mild cognitive impairment. J Alzheimers Dis70, 303–314.
36.
AlbertiKG, ZimmetPZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med15, 539–553.
37.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
38.
CuiY, ChenXB, LiuLY, XieW, WuY, WuQH, WangDC (2015) Gas chromatography-mass spectrometry analysis of the free fatty acids in serum obtained from patients with Alzheimer’s disease. Biomed Mater Eng26, S2165–S2177.
39.
GoldbourtU, YaariS, MedalieJH (1993) Factors predictive of long-term coronary heart disease mortality among 10,059 male Israeli civil servants and municipal employees. A 23-year mortality follow-up in the Israeli Ischemic Heart Disease Study. Cardiology82, 100–121.
40.
InnisSM (2007) Fatty acids and early human development. Early Hum Dev83, 761–766.
41.
PerryRJ, HodgesJR (1999) Attention and executive deficits in Alzheimer’s disease. A critical review. Brain122 (Pt 3), 383–404.
42.
BraccoL, BessiV, PadiglioniS, MariniS, PepeuG (2014) Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer’s disease patients. J Alzheimers Dis40, 737–742.
43.
PerryRJ, WatsonP, HodgesJR (2000) The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer’s disease: Relationship to episodic and semantic memory impairment. Neuropsychologia38, 252–271.
SarterM, GehringWJ, KozakR (2006) More attention must be paid: The neurobiology of attentional effort. Brain Res Rev51, 145–160.
46.
ParasuramanR, MartinA (1994) Cognition in Alzheimer’s disease: Disorders of attention and semantic knowledge. Curr Opin Neurobiol4, 237–244.
47.
FoldiNS, LoboscoJJ, SchaeferLA (2002) The effect of attentional dysfunction in Alzheimer’s disease: Theoretical and practical implications. Semin Speech Lang23, 139–150.
HarrSD, UintL, HollisterR, HymanBT, MendezAJ (1996) Brain expression of apolipoproteins E, J, and A-I in Alzheimer’s disease. J Neurochem66, 2429–2435.
50.
SongF, PoljakA, CrawfordJ, KochanNA, WenW, CameronB, LuxO, BrodatyH, MatherK, SmytheGA, SachdevPS (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS One7, e34078.
51.
ChistiakovDA, OrekhovAN, BobryshevYV (2016) ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest96, 708–718.
52.
TallAR (1998) An overview of reverse cholesterol transport.A. Eur Heart J19(Suppl A), 31–35.
53.
LouF, LiM, LiuN, LiX, RenY, LuoX (2019) The polymorphism of SREBF1 gene rs11868035 G/A is associated with susceptibility to Parkinson’s disease in a Chinese population. Int J Neurosci129, 660–665.
54.
PengXE, ChenFL, LiuW, HuZ, LinX (2016) Lack of association between SREBF-1c gene polymorphisms and risk of non-alcoholic fatty liver disease in a Chinese Han population. Sci Rep6, 32110.
55.
TangY, LiYM, ZhangM, ChenYQ, SunQ (2019)
ɛ3/4 genotype of the apolipoprotein E is associated with higher risk of Alzheimer’s disease in patients with type 2 diabetes mellitus. Gene703, 65–70.
